Dr. Craig Rosenfeld received his B.A. and M.D. degrees from the University of Missouri in Kansas City, and completed his internship and residency at the University of Nebraska Medical Center. Dr. Rosenfeld completed fellowships in Hematology and Oncology at the University of Kansas Medical Center. After completing his fellowships, he joined the Faculty of University of Pittsburgh. In 1990, Dr. Rosenfeld was appointed Director of the Bone Marrow Transplant Program at the Western Pennsylvania Cancer Institute. In 1994, Dr. Rosenfeld moved to Dallas to establish and direct the Bone Marrow Transplant Program at Medical City Dallas Hospital. In 2002, Dr. Rosenfeld was appointed Chief Scientific Officer at SuperGen, Inc. While Chief Scientific Officer, Senior Vice President, and later as Chairman of the Medical Advisory Board and Consultant for Dacogen NDA, Dr. Rosenfeld directed the pivotal trials to completion, leading to submission and FDA approval of Dacogen. In 2005, Dr. Rosenfeld co-founded The Vaccine Company, and served as Chief Medical Officer and Executive Vice President raising several million in private capital.
Dr. Rosenfeld currently serves on the Texas Israel Chamber of Commerce. He is a member of the American Society of Clinical Oncology, American Society of Hematology, Dallas County Medical Society, and Texas Medical Association. Dr. Rosenfeld received the 2008 Dallas Humanitarian of the Year Award from B’nai Zion. During almost 20 years of practice, Dr. Rosenfeld has devised, conducted, and led numerous clinical research protocols from pre-clinical to FDA approval. He has authored or co-authored close to 100 publications in book chapters and peer reviewed journals. Additionally, Dr. Rosenfeld has presented original research and expert review at international symposia including the American Society of Hematology and the American Society of Clinical Oncology.